International Assets Investment Management LLC Sells 527,447 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

International Assets Investment Management LLC lessened its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 99.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,013 shares of the company’s stock after selling 527,447 shares during the period. International Assets Investment Management LLC’s holdings in IDEXX Laboratories were worth $414,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the stock. Private Advisor Group LLC grew its stake in shares of IDEXX Laboratories by 8.7% in the 2nd quarter. Private Advisor Group LLC now owns 2,287 shares of the company’s stock worth $1,114,000 after acquiring an additional 183 shares in the last quarter. Ashton Thomas Private Wealth LLC purchased a new stake in IDEXX Laboratories in the 2nd quarter valued at about $89,000. Main Street Financial Solutions LLC grew its holdings in shares of IDEXX Laboratories by 5.5% in the second quarter. Main Street Financial Solutions LLC now owns 657 shares of the company’s stock valued at $320,000 after acquiring an additional 34 shares in the last quarter. DekaBank Deutsche Girozentrale boosted its position in IDEXX Laboratories by 3.8% in the second quarter. DekaBank Deutsche Girozentrale now owns 54,220 shares of the company’s stock worth $26,721,000 after purchasing an additional 1,963 shares during the last quarter. Finally, Meeder Advisory Services Inc. increased its position in shares of IDEXX Laboratories by 34.0% during the 2nd quarter. Meeder Advisory Services Inc. now owns 2,129 shares of the company’s stock valued at $1,037,000 after purchasing an additional 540 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 344 shares of the firm’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total transaction of $144,631.36. Following the completion of the transaction, the director now owns 905 shares in the company, valued at $380,498.20. This trade represents a 27.54 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 2.11% of the company’s stock.

IDEXX Laboratories Trading Down 3.3 %

IDEXX Laboratories stock opened at $418.05 on Friday. The business has a 50-day simple moving average of $423.76 and a two-hundred day simple moving average of $460.18. The company has a quick ratio of 1.03, a current ratio of 1.42 and a debt-to-equity ratio of 0.32. The company has a market cap of $34.23 billion, a P/E ratio of 40.31, a P/E/G ratio of 3.94 and a beta of 1.36. IDEXX Laboratories, Inc. has a 52-week low of $398.50 and a 52-week high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Thursday, October 31st. The company reported $2.80 EPS for the quarter, topping analysts’ consensus estimates of $2.69 by $0.11. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The business had revenue of $975.50 million during the quarter, compared to analysts’ expectations of $980.32 million. During the same quarter in the prior year, the business posted $2.53 earnings per share. The business’s quarterly revenue was up 6.6% on a year-over-year basis. Analysts predict that IDEXX Laboratories, Inc. will post 10.44 EPS for the current year.

Wall Street Analysts Forecast Growth

IDXX has been the subject of a number of recent research reports. Piper Sandler reissued a “neutral” rating and issued a $435.00 target price (down from $520.00) on shares of IDEXX Laboratories in a research report on Monday, November 4th. Barclays reduced their price objective on shares of IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating for the company in a research note on Monday, November 4th. Leerink Partnrs upgraded IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. Stifel Nicolaus cut their price objective on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a research note on Thursday, October 10th. Finally, Leerink Partners assumed coverage on IDEXX Laboratories in a research report on Monday, December 2nd. They set an “outperform” rating and a $500.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and an average price target of $539.63.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.